Cryosurgical ablation of the prostate for localized adenocarcinoma

A preliminary experience

Robert Wake, Robert S. Hollabaugh, Kevin H. Bond

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: Cryosurgical ablation of the prostate has recently become recognized as a therapeutic option in the treatment of localized adenocarcinoma of the prostate. To assess the efficacy of cryoablation in this disease process several centers have instituted treatment protocols. Materials and Methods: Our overall series includes 117 ultrasound guided percutaneous transperineal cryoablations performed on 104 patients with localized adenocarcinoma of the prostate. Followup consisted of digital rectal examinations and measurement of prostate specific antigen levels at 3- month intervals after cryosurgery. Additionally, prostate biopsies were obtained 3 to 6 months postoperatively. Results: Of 63 patients who underwent initial cryosurgery and followup biopsy 47 (75%) had negative findings. Of the 16 patients with positive biopsies 10 consented to undergo a second cryosurgical ablation, and 7 of these patients subsequently had negative followup biopsies. Therefore, our disease-free rate at 3 months after 1 or 2 cryosurgical procedures was 95%. A total of 46 protocol patients in our series completed 12 months of evaluation and 40 (87%) had no evidence of disease. This same cohort showed only minimal disease progression, with disease-free rates of 96, 93, 87 and 87% at 3, 6, 9 and 12 months, respectively. Major complications were infrequent. Conclusions: At 1-year followup our clinical experience shows cryoablation of the prostate to be an effective therapy in select cases of prostatic adenocarcinoma. Long-term efficacy is still in question but, based on current disease-free rates, this therapeutic modality merits continued clinical investigation.

Original languageEnglish (US)
Pages (from-to)1663-1666
Number of pages4
JournalJournal of Urology
Volume155
Issue number5
DOIs
StatePublished - Jan 1 1996

Fingerprint

Cryosurgery
Prostate
Adenocarcinoma
Biopsy
Digital Rectal Examination
Therapeutics
Prostate-Specific Antigen
Clinical Protocols
Disease Progression

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Cryosurgical ablation of the prostate for localized adenocarcinoma : A preliminary experience. / Wake, Robert; Hollabaugh, Robert S.; Bond, Kevin H.

In: Journal of Urology, Vol. 155, No. 5, 01.01.1996, p. 1663-1666.

Research output: Contribution to journalArticle

Wake, Robert ; Hollabaugh, Robert S. ; Bond, Kevin H. / Cryosurgical ablation of the prostate for localized adenocarcinoma : A preliminary experience. In: Journal of Urology. 1996 ; Vol. 155, No. 5. pp. 1663-1666.
@article{6e8874ed66d54650992a7f0f5d8c5219,
title = "Cryosurgical ablation of the prostate for localized adenocarcinoma: A preliminary experience",
abstract = "Purpose: Cryosurgical ablation of the prostate has recently become recognized as a therapeutic option in the treatment of localized adenocarcinoma of the prostate. To assess the efficacy of cryoablation in this disease process several centers have instituted treatment protocols. Materials and Methods: Our overall series includes 117 ultrasound guided percutaneous transperineal cryoablations performed on 104 patients with localized adenocarcinoma of the prostate. Followup consisted of digital rectal examinations and measurement of prostate specific antigen levels at 3- month intervals after cryosurgery. Additionally, prostate biopsies were obtained 3 to 6 months postoperatively. Results: Of 63 patients who underwent initial cryosurgery and followup biopsy 47 (75{\%}) had negative findings. Of the 16 patients with positive biopsies 10 consented to undergo a second cryosurgical ablation, and 7 of these patients subsequently had negative followup biopsies. Therefore, our disease-free rate at 3 months after 1 or 2 cryosurgical procedures was 95{\%}. A total of 46 protocol patients in our series completed 12 months of evaluation and 40 (87{\%}) had no evidence of disease. This same cohort showed only minimal disease progression, with disease-free rates of 96, 93, 87 and 87{\%} at 3, 6, 9 and 12 months, respectively. Major complications were infrequent. Conclusions: At 1-year followup our clinical experience shows cryoablation of the prostate to be an effective therapy in select cases of prostatic adenocarcinoma. Long-term efficacy is still in question but, based on current disease-free rates, this therapeutic modality merits continued clinical investigation.",
author = "Robert Wake and Hollabaugh, {Robert S.} and Bond, {Kevin H.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(01)66158-5",
language = "English (US)",
volume = "155",
pages = "1663--1666",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Cryosurgical ablation of the prostate for localized adenocarcinoma

T2 - A preliminary experience

AU - Wake, Robert

AU - Hollabaugh, Robert S.

AU - Bond, Kevin H.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Purpose: Cryosurgical ablation of the prostate has recently become recognized as a therapeutic option in the treatment of localized adenocarcinoma of the prostate. To assess the efficacy of cryoablation in this disease process several centers have instituted treatment protocols. Materials and Methods: Our overall series includes 117 ultrasound guided percutaneous transperineal cryoablations performed on 104 patients with localized adenocarcinoma of the prostate. Followup consisted of digital rectal examinations and measurement of prostate specific antigen levels at 3- month intervals after cryosurgery. Additionally, prostate biopsies were obtained 3 to 6 months postoperatively. Results: Of 63 patients who underwent initial cryosurgery and followup biopsy 47 (75%) had negative findings. Of the 16 patients with positive biopsies 10 consented to undergo a second cryosurgical ablation, and 7 of these patients subsequently had negative followup biopsies. Therefore, our disease-free rate at 3 months after 1 or 2 cryosurgical procedures was 95%. A total of 46 protocol patients in our series completed 12 months of evaluation and 40 (87%) had no evidence of disease. This same cohort showed only minimal disease progression, with disease-free rates of 96, 93, 87 and 87% at 3, 6, 9 and 12 months, respectively. Major complications were infrequent. Conclusions: At 1-year followup our clinical experience shows cryoablation of the prostate to be an effective therapy in select cases of prostatic adenocarcinoma. Long-term efficacy is still in question but, based on current disease-free rates, this therapeutic modality merits continued clinical investigation.

AB - Purpose: Cryosurgical ablation of the prostate has recently become recognized as a therapeutic option in the treatment of localized adenocarcinoma of the prostate. To assess the efficacy of cryoablation in this disease process several centers have instituted treatment protocols. Materials and Methods: Our overall series includes 117 ultrasound guided percutaneous transperineal cryoablations performed on 104 patients with localized adenocarcinoma of the prostate. Followup consisted of digital rectal examinations and measurement of prostate specific antigen levels at 3- month intervals after cryosurgery. Additionally, prostate biopsies were obtained 3 to 6 months postoperatively. Results: Of 63 patients who underwent initial cryosurgery and followup biopsy 47 (75%) had negative findings. Of the 16 patients with positive biopsies 10 consented to undergo a second cryosurgical ablation, and 7 of these patients subsequently had negative followup biopsies. Therefore, our disease-free rate at 3 months after 1 or 2 cryosurgical procedures was 95%. A total of 46 protocol patients in our series completed 12 months of evaluation and 40 (87%) had no evidence of disease. This same cohort showed only minimal disease progression, with disease-free rates of 96, 93, 87 and 87% at 3, 6, 9 and 12 months, respectively. Major complications were infrequent. Conclusions: At 1-year followup our clinical experience shows cryoablation of the prostate to be an effective therapy in select cases of prostatic adenocarcinoma. Long-term efficacy is still in question but, based on current disease-free rates, this therapeutic modality merits continued clinical investigation.

UR - http://www.scopus.com/inward/record.url?scp=0029931793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029931793&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)66158-5

DO - 10.1016/S0022-5347(01)66158-5

M3 - Article

VL - 155

SP - 1663

EP - 1666

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -